Details for Patent: 8,809,292
✉ Email this page to a colleague
Which drugs does patent 8,809,292 protect, and when does it expire?
Patent 8,809,292 protects LEQVIO and is included in one NDA.
This patent has forty-two patent family members in fourteen countries.
Summary for Patent: 8,809,292
Title: | Compositions and methods for inhibiting expression of the PCSK9 gene |
Abstract: | The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression. |
Inventor(s): | Tan; Pamela (Kulmbach, DE), Bramlage; Birgit (Kulmbach, DE), Frank-Kamenetsky; Maria (Brookline, MA), Fitzgerald; Kevin (Brookline, MA), Akinc; Akin (Needham, MA), Kotelianski; Victor E. (Boston, MA) |
Assignee: | Alnylam Pharmaceuticals, Inc (Cambridge, MA) |
Application Number: | 13/472,438 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; |
Drugs Protected by US Patent 8,809,292
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | LEQVIO | inclisiran sodium | SOLUTION;SUBCUTANEOUS | 214012-001 | Dec 22, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | AS AN ADJUNCT TO DIET AND STATIN THERAPY FOR THE TREATMENT OF ADULTS WITH PRIMARY HYPERLIPIDEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH), BY INHIBITING EXPRESSION OF THE PCSK9 GENE | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,809,292
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2007249329 | ⤷ Try a Trial | |||
Australia | 2010241357 | ⤷ Try a Trial | |||
Australia | 2012261570 | ⤷ Try a Trial | |||
Australia | 2016203687 | ⤷ Try a Trial | |||
Canada | 2651839 | ⤷ Try a Trial | |||
Canada | 2915441 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |